With a 5-year survival rate of 84%, the "weapon" of the United States to treat endometrial cancer is precision surgery and rational medication!

Endometrial cancer, that is, uterine cancer, 420,000 new cancers of endometrial cancer in 2020, ranking sixth among common tumors in women, is a common gynecological malignancy

▲5-year survival rate data of endometrial cancer in the United States

01 Surgical treatment

Surgery is the mainstay of endometrial cancer treatment, and even advanced endometrial cancer can benefit from

In clinical treatment, the surgical regimen can be selected according to the degree of invasion of the tumor, if the tumor has not spread outside the uterus, the tumor is radically cured by hysterectomy combined with bilateral salpingo-oophorectomy (BSO), and lymphadenectomy is used to determine whether the cancer has metastasized; If endometrial cancer has progressed to an advanced stage, hysterectomy can also be effective in improving a patient's prognosis

In recent years, with the development of minimally invasive technology, laparoscopic surgery and da Vinci robotic surgery have become more and more widely

A study published in 2017 included 760 patients with early-stage endometrial cancer and evaluated the effectiveness and safety of laparoscopic total hysterectomy versus open total hysterectomy

Another 2020 study evaluated the effects

However, it should be noted that whether it is da Vinci robotic surgery, laparoscopic surgery or open surgery, it needs to be carried out by experienced surgeons, experienced doctors have a deep perception of the details of the operation, can predict the danger of surgery, possible problems in surgery, so as to prevent in advance, while improving the success rate of surgery, reduce the harm

02 Targeted and immunotherapy

Advanced endometrial cancers often prolong survival with drugs such as chemotherapy, hormone therapy, targeted therapy, and immunotherapy

At present, innovative therapies such as Lenvatinib (Lenvima), bevacizumab, mTOR inhibitors – Everolimus (Afinitor) and Temsirolimus (Torisel), PD-1 inhibitors Pembrolizumab (Keytruda) and dostarlimab (Jemperli) have all been approved by the FDA for the treatment of endometrial cancer.

In addition, the combination of immunity + targeting has also brought new options

In July 2021, the U.

In January, the New England Journal of Medicine published findings showing that the combination of Keytruda+Lenvima significantly prolonged the survival of

： ，